RAMON RAMIREZ: Open Payments
NPI 1760008304 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,804 in 175 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $1,795 · 2025 $3,804
Food & beverage: $3,729Education: $75
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 32 | $1,080 |
| GlaxoSmithKline, LLC. | 28 | $460 |
| GENZYME CORPORATION | 16 | $294 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $257 |
| Regeneron Healthcare Solutions, Inc. | 17 | $233 |
| Mallinckrodt Hospital Products Inc. | 6 | $182 |
| Viatris Specialty LLC | 11 | $171 |
| Pulmonx Corporation | 2 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $154 |
| United Therapeutics Corporation | 5 | $145 |
Products named: DUPIXENT, FASENRA, TRELEGY ELLIPTA, NUCALA, OFEV, AIRSUPRA, ACTHAR, YUPELRI.
Industry payments across OK — which companies pay providers there.
